Activity of cefiderocol and comparators against isolates from cancer patients

Kenneth V.I. Rolston, Baghat Gerges, Samuel Shelburne, Samuel L. Aitken, Issam Raad, Randall A. Prince

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae. No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.

Original languageEnglish (US)
Article numbere01955-19
JournalAntimicrobial agents and chemotherapy
Volume64
Issue number5
DOIs
StatePublished - May 1 2020

Keywords

  • Cefiderocol
  • Gram-negative isolates
  • Pseudomonas aeruginosa
  • Stenotrophomonas maltophilia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Activity of cefiderocol and comparators against isolates from cancer patients'. Together they form a unique fingerprint.

  • Cite this